Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: Comparison of a systemic vs. a mucosal booster schedule

24Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

We compared the immunogenicity of two vaccination schedules with either a systemic or a mucosal booster, both following a mucosal primary vaccination with a recombinant outer membrane fusion protein of Pseudomonas aeruginosa (OprF-I) in 12 healthy volunteers. The systemic booster induced higher levels of OprF-I-specific serum antibodies of IgG isotype, with a mean±S.E.M. of 32.6±7.8×107 enzyme-linked immunosorbent assay (ELISA) units (EU) as compared to the nasal booster with 14.6±2.1×107 EU (P=0.05). Specific serum IgA antibodies and antibodies in saliva did not differ between the two vaccination groups. We conclude that a combined mucosal/systemic vaccination with the OprF-I vaccine may offer an enhanced systemic immunogenicity. Further studies on the long-term immunogenicity and induction of antibodies on the respiratory airway surface are warranted. © 2003 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.

Cite

CITATION STYLE

APA

Göcke, K., Baumann, U., Hagemann, H., Gabelsberger, J., Hahn, H., Freihorst, J., & Von Specht, B. U. (2003). Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: Comparison of a systemic vs. a mucosal booster schedule. FEMS Immunology and Medical Microbiology, 37(2–3), 167–171. https://doi.org/10.1016/S0928-8244(03)00094-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free